Cargando…

Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort

BACKGROUND: Treatment options for patients with urothelial cancer (UC) refractory to platinum and immunotherapy are limited and survival is short. Enfortumab vedotin (EV) is a monoclonal anti-NECTIN4 antibody conjugated to monomethyl auristatin. It was recently approved because of superior survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zschäbitz, Stefanie, Biernath, Nadine, Hilser, Thomas, Höllein, Alexander, Zengerling, Friedemann, Cascucelli, Jozefina, Paffenholz, Pia, Seidl, Daniel, Lutz, Christoph, Schlack, Katrin, Kingreen, Dorothea, Klümper, Niklas, Ivanyi, Philipp, von Amsberg, Gunhild, Heers, Hendrik, Roghmann, Florian, Tauber, Robert L., Cathomas, Richard, Hofer, Luisa, Niegisch, Günter, Klee, Melanie, Ehrenberg, Roland, Hassler, Andreas, Hadaschik, Boris A., Grünwald, Viktor, Darr, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Urothelial Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334227/ https://www.ncbi.nlm.nih.gov/pubmed/37441344 http://dx.doi.org/10.1016/j.euros.2023.04.018

Ejemplares similares

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
por: Klümper, Niklas, et al.
Publicado: (2023)

Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver?
por: Rodler, Severin, et al.
Publicado: (2020)

Postoperative Chemotherapy Bladder Instillation After Radical Nephroureterectomy: Results of a European Survey from the Young Academic Urologist Urothelial Cancer Group
por: Dobé, Tom-Régis, et al.
Publicado: (2020)

Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020)

Drug extravasation with Enfortumab vedotin
por: Grant, Christopher Ryan, et al.
Publicado: (2023)

Flexural Exanthema From Enfortumab Vedotin
por: Keerty, Dinesh, et al.
Publicado: (2020)

Prediction of Metastatic Patterns in Bladder Cancer: Spatiotemporal Progression and Development of a Novel, Web-based Platform for Clinical Utility
por: Mason, Jeremy, et al.
Publicado: (2021)

Intraoperative Mitomycin C Bladder Instillation During Radical Nephroureterectomy Is Feasible and Safe
por: Nadler, Naomi, et al.
Publicado: (2021)

Comparative Outcomes of Primary Versus Recurrent High-risk Non–muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study
por: Grossmann, Nico C., et al.
Publicado: (2022)

STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes
por: Gordon, Naheema S., et al.
Publicado: (2022)

Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study
por: Omland, Lise H., et al.
Publicado: (2020)

The Association Between Renal Function Decline and the Incidence of Urothelial Carcinoma: A 16-year Retrospective Cohort Study in Taiwan
por: Chuang, Yung-Hsin, et al.
Publicado: (2021)

Long-term Follow-up After En Bloc Transurethral Resection of Non–muscle-invasive Bladder Cancer: Results from a Single-center Experience
por: Paciotti, Marco, et al.
Publicado: (2021)

Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis
por: Khalid, Sidra, et al.
Publicado: (2020)

Survival and Long-term Effects of Kidney-sparing Surgery Versus Radical Nephroureterectomy on Kidney Function in Patients with Upper Urinary Tract Urothelial Carcinoma
por: Hendriks, Nora, et al.
Publicado: (2022)

Radical Nephroureterectomy Tetrafecta: A Proposal Reporting Surgical Strategy Quality at Surgery
por: Soria, Francesco, et al.
Publicado: (2022)

The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy
por: D'Andrea, David, et al.
Publicado: (2022)

Site-specific Risk Stratification Models for Postoperative Recurrence and Survival Prediction in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: Better Stratification for Adjuvant Therapy
por: Miyake, Makito, et al.
Publicado: (2022)

Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy
por: Marcq, Gautier, et al.
Publicado: (2022)

International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members
por: Beijert, Irene J., et al.
Publicado: (2023)

Single-nucleus and Spatially Resolved Intratumor Subtype Heterogeneity in Bladder Cancer
por: Lindskrog, Sia V., et al.
Publicado: (2023)

Is a Single Nephrographic Phase Computed Tomography Sufficient for Detecting Urothelial Carcinoma in Patients with Visible Haematuria? A Prospective Paired Noninferiority Comparison
por: Galtung, Kristina F., et al.
Publicado: (2023)

Location of Retroperitoneal Lymph Node Metastases in Upper Tract Urothelial Carcinoma: Results from a Prospective Lymph Node Mapping Study
por: Bobjer, Johannes, et al.
Publicado: (2023)

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
por: Hanna, Kirollos S.
Publicado: (2020)

THU354 Enfortumab Vedotin Induced Refractory Hyperglycemia
por: Hussein, Marwah, et al.
Publicado: (2023)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
por: Moussa, Mohamad, et al.
Publicado: (2021)

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin
por: Homma, Takamasa, et al.
Publicado: (2023)

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
por: Fahey, Catherine C., et al.
Publicado: (2023)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)

A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis
por: Francis, Andrea, et al.
Publicado: (2020)

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
por: Thibodeau, Alexa, et al.
Publicado: (2021)

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
por: Wu, Qiuji, et al.
Publicado: (2022)

Cutaneous reactions with enfortumab vedotin: A case series and review of the literature
por: Dobry, Allison S., et al.
Publicado: (2021)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
por: Shafique, Muhammad Ashir, et al.
Publicado: (2023)

Current status of the focused series “Urothelial Carcinoma”
por: Yuk, Hyeong Dong, et al.
Publicado: (2020)

Prognostic Value of Tumor Size in Patients with Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis
por: Ma, Runzhuo, et al.
Publicado: (2022)

Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies
por: Mertens, Laura S., et al.
Publicado: (2023)

Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
por: Hoffman-Censits, Jean, et al.
Publicado: (2022)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
por: Vulsteke, Christof, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5an8a77ev73guum9eho851ns36